Hallucinogens and Their Therapeutic Use: A Literature Review.
Matthew J Begola, Jason E Schillerstrom
Journal of Psychiatric Practice September 1, 2019 DOI: 10.1097/pra.0000000000000409 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | ayahuasca ibogaine ketamine lysergic acid diethylamide 3 4-methylenedioxymethamphetamine psilocybin |
| Keywords | Psychedelics Hallucinogens Entheogens Psychedelic drugs Psychotropic substances Psychiatric disorders Behavioral health Psychological well-being Psychotherapy Mental health treatment Therapeutic applications Drug research Clinical trials Medical research Pharmaceutical research Substance evaluation |
| Citations | 20 |
| Key findings | Most studies reviewed showed significant associations with improvement in psychiatric conditions, but definitive conclusions were limited by small samples, inconsistent measures, and poor study design. |
Abstract
The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated. However, it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design. To properly assess the risks and potential benefits of hallucinogens in psychiatric treatment, there is a need for well designed, standardized studies that demonstrate the impact of hallucinogenic substances on psychiatric conditions.
Citations in the library
Cited by 13
- Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey Journal of Psychoactive Drugs August 19, 2021
- Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe Psychopharmacology May 25, 2021
- Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment Expert Opinion on Drug Safety April 15, 2022
- Ayahuasca and the traveller: A scoping review of risks and possible benefits Travel Medicine and Infectious Disease November 1, 2021
- Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders Frontiers in Pharmacology June 28, 2022
and 8 more in the library
Cites 23
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology March 8, 2012
- Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Brazilian Journal of Psychiatry March 1, 2015
- Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction Current Drug Abuse Reviews January 9, 2015
and 18 more in the library